Cancer pain originates through multiple pathways. Tumor growth can compress or infiltrate peripheral nerves, triggering nociceptive signals that the brain interprets as pain. Approximately 30-50% of cancer patients experience pain at diagnosis, and that number rises to 70-90% in advanced stages as tumors expand and metastasize to bone, visceral organs, or neural structures.
Chemotherapy-induced peripheral neuropathy affects up to 68% of patients within the first month of treatment, damaging the small nerve fibers responsible for sensation. This creates a paradox where the treatment designed to fight cancer simultaneously generates new pain through demyelination and axonal degeneration of peripheral nerves.
Central sensitization compounds the problem as persistent pain signals rewire the spinal cord and brain, amplifying pain perception over time. NMDA receptors in the dorsal horn become hyperactivated, lowering pain thresholds and causing normally painless stimuli to register as painful, a phenomenon called allodynia that makes even gentle touch unbearable.
